In Reply For reference, we consider all initial, anticancer drug authorizations, and report mean treatment effects. Fojo et al1 consider initial and extension drug authorizations for only solid tumors, and instead report medians. We present drug overall survival (OS) benefits individually. Unlike Fojo et al, we then estimate the total impact on patient OS between 2003 and 2013. Where appropriate, OS benefits were combined sequentially to reflect drug development—we intentionally did not divide by 2. For example, within this period, lapatinib’s approval was based on a comparison against capecitabine monotherapy; T-DM1 was later compared against lapatinib + capecitabine. Drug OS gains were 0.3 to 2.4 and 5.8 months, respectively. Eligible patients would have therefore seen an expected OS increase of 6.1 to 8.2 months between 2003 and 2013. Dividing by 2 would redundantly estimate average OS benefits per new drug.
Salas-Vega S, Mossialos E. Overestimating the Benefit of Cancer Drugs—Reply . JAMA Oncol. Published online July 13, 2017. doi:10.1001/jamaoncol.2017.1976
* * SCHEDULED MAINTENANCE * *
The JAMA Network Sites will be conducting routine maintenance from 10/20/2017 through 10/21/2017. During this window access to content and authentication may be intermittently available. The JAMA Store will be completely unavailable during the maintenance window.